Related Experiment Video
Updated: Apr 15, 2026

Author Spotlight: Alleviating Nausea and Vomiting in Pregnancy with Safe and Effective Auricular Acupuncture
Published on: August 4, 2023
Akathisia Induced by Metoclopramide in a Pregnant Woman With Nausea and Vomiting: A Case Report
Ryohei Nakamura1, Keisuke Noto1, Toshinori Shirata1
1Department of Psychiatry, Yamagata University School of Medicine, Yamagata, Japan.
Background:
Nausea and vomiting are common during pregnancy and can significantly impair maternal well-being. Metoclopramide is widely used to treat these symptoms but may cause extrapyramidal side effects, including akathisia. Akathisia is characterized by inner-restlessness and psychomotor agitation, which can be difficult to distinguish from perinatal anxiety disorders due to symptom overlap. Reports of metoclopramide-induced akathisia during pregnancy are limited.
Case Presentation:
We report a case of metoclopramide-induced akathisia in a pregnant woman at 33 weeks of gestation with nausea and vomiting. She had been taking dextromethorphan for a COVID-19-related cough prior to admission. She was hospitalized for threatened preterm labor with abdominal tightness, and intravenous bolus infusions of metoclopramide were initiated for nausea, vomiting, and appetite loss. Shortly thereafter, she developed limb tremors and insomnia, followed by severe inner restlessness and psychomotor agitation. Suspecting anxiety disorders or akathisia, metoclopramide was discontinued and diazepam was started. Her symptoms improved within 3 days, with no recurrence after discontinuation of diazepam. Based on the clinical course and temporal relationship with metoclopramide administration, metoclopramide-induced akathisia was considered the most likely diagnosis.
Conclusions:
This case suggests that metoclopramide-induced akathisia can occur during pregnancy and may be misdiagnosed as a perinatal anxiety disorder. Rapid intravenous bolus administration is a known risk factor for metoclopramide-induced akathisia and may have increased the risk in this patient. In addition, a possible pharmacological interaction between metoclopramide and dextromethorphan, including a potential CYP2D6-related pharmacokinetic effect and central dopaminergic pharmacodynamic effect, may have contributed to akathisia. Greater awareness of this adverse effect may facilitate early recognition and appropriate management.
More Related Videos
05:56Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
Published on: June 21, 2024
08:07Author Spotlight: Advancing Labor Management Through Electromyometrial Imaging for Understanding Uterine Contractions
Published on: May 26, 2023
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Pathophysiology of Vomiting
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists